UBS AM
ORIC icon

UBS AM’s Oric Pharmaceuticals ORIC Stock Holding History

UBS AM’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$687K Buy
63,470
+9,231
+17% +$83.7K ﹤0.01% 2457
2026
Q1 		$687K Buy
54,239
+3,457
+7% +$39.2K ﹤0.01% 2464
2025
Q4 		$415K Buy
50,782
+27,547
+119% +$317K ﹤0.01% 2359
2025
Q3 		$279K Buy
+23,235
New +$244K ﹤0.01% 2208
2025
Q2 		– Sell
-509,179
Closed -$2.84M – 2695
2025
Q1 		$2.84M Buy
509,179
+473,600
+1,331% +$4.14M ﹤0.01% 1834
2024
Q4 		$287K Buy
35,579
+12,545
+54% +$115K ﹤0.01% 2616
2024
Q3 		$236K Sell
23,034
-19,286
-46% -$191K ﹤0.01% 2747
2024
Q2 		$299K Buy
+42,320
New +$379K ﹤0.01% 2722
2022
Q2 		– Sell
-13,033
Closed -$69.6K – 2747
2022
Q1 		$69.6K Hold
13,033
– – ﹤0.01% 2754
2021
Q4 		$192K Hold
13,033
– – ﹤0.01% 2770
2021
Q3 		$273K Hold
13,033
– – ﹤0.01% 2637
2021
Q2 		$231K Buy
13,033
+2,033
+18% +$44.5K ﹤0.01% 2694
2021
Q1 		$270K Buy
11,000
+3,600
+49% +$114K ﹤0.01% 2506
2020
Q4 		$250K Buy
+7,400
New +$212K ﹤0.01% 2453
2020
Q3 		– Sell
-12,775
Closed -$431K – 2503
2020
Q2 		$431K Buy
+12,775
New +$408K ﹤0.01% 2178

Other funds holding ORIC

NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

UBS AM's ORIC Position: Q2 2026 in Review

UBS AM increased its Oric Pharmaceuticals (ORIC) stake by 17% in Q2 2026, buying an estimated $83.7K and bringing the position to 63,470 shares worth $687K. The position accounts for ﹤0.01% of the portfolio, ranked #2457.

UBS AM first reported a position in ORIC in Q2 2020 and has held it in 15 quarters since. The position peaked at $2.84M in Q1 2025. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

  • UBS AM held 63,470 shares of Oric Pharmaceuticals worth $687K as of Q2 2026.
  • UBS AM bought 9,231 Oric Pharmaceuticals shares in Q2 2026, an estimated $83.7K.
  • Oric Pharmaceuticals made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #2457 holding.
  • UBS AM first reported a position in Oric Pharmaceuticals in Q2 2020 and has held it in 15 quarters since.
  • UBS AM's Oric Pharmaceuticals position peaked at $2.84M in Q1 2025.
  • 181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.